Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

DOI Full Paper Access

99

Citations

16

References

2020

Year

Bruce Cree, Gary Cutter, Jerry S. Wolinsky, Mark S. Freedman, Gavin Giovannoni, Hans-Peter Hartung, Douglas L. Arnold, Jens Kühle, Valerie J. Block, Frederick Munschauer,

The Lancet Neurology

Abstract

MedDay Pharmaceuticals.

References

	Year	Citations

Page 1